Literature DB >> 22437251

Management and outcome of salivary duct carcinoma in major salivary glands.

Elina Salovaara1, Olli Hakala, Leif Bäck, Petri Koivunen, Kauko Saarilahti, Fabricio Passador-Santos, Ilmo Leivo, Antti A Mäkitie.   

Abstract

Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with poor prognosis. Its histomorphology is distinctly reminiscent of the ductal carcinoma of the breast. We reviewed the treatment and outcome of SDCs at a single tertiary care centre. Twenty-five cases of SDC of major salivary gland origin, diagnosed and treated at the Department of Otolaryngology, Head and Neck Surgery, Helsinki University Central Hospital, Helsinki, Finland, during a 14-year period from 1997 to 2011, were reviewed retrospectively. Survival outcome was analyzed for 18 patients with a minimum follow-up of 24 months. There were 16 male (64 %) and 9 female (36 %) patients with a median age of 61 years (range 36-82 years). The majority of the cases occurred in the parotid gland (n = 21, 84 %) followed by the submandibular gland (n = 4, 16 %). The primary treatment consisted of surgical resection in all cases and 17 (68 %) patients also underwent neck dissection. Most of the patients (n = 18, 72 %) were treated with postoperative radiotherapy. Seven patients (28 %) had a disease recurrence within a median follow-up time of 15 months (range 3-27 months). In the group (n = 18) with a minimum follow-up time of 24 months, the 2- and 5-year overall and disease-specific survival rates were 66, 41 % and 75, 55 %, respectively. These results confirm the aggressive nature of SDCs in major salivary glands. Diagnostics and management of these tumours need to be centralized in experienced surgical Head and Neck Oncology Centres, and new treatment strategies should be investigated.

Entities:  

Mesh:

Year:  2012        PMID: 22437251     DOI: 10.1007/s00405-012-1997-4

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  26 in total

1.  Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy.

Authors:  Trevor M Feinstein; Stephen Y Lai; Diana Lenzner; William Gooding; Robert L Ferris; Jennifer R Grandis; Eugene N Myers; Jonas T Johnson; Dwight E Heron; Athanassios Argiris
Journal:  Head Neck       Date:  2011-01-31       Impact factor: 3.147

2.  [Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma].

Authors:  O Kleinsasser; H J Klein; G Hübner
Journal:  Arch Klin Exp Ohren Nasen Kehlkopfheilkd       Date:  1968

Review 3.  Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases.

Authors:  J E Lewis; B C McKinney; L H Weiland; J A Ferreiro; K D Olsen
Journal:  Cancer       Date:  1996-01-15       Impact factor: 6.860

4.  Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.

Authors:  Michael Jaehne; Kerstin Roeser; Thorsten Jaekel; Jan David Schepers; Natalie Albert; Thomas Löning
Journal:  Cancer       Date:  2005-06-15       Impact factor: 6.860

5.  Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.

Authors:  Michelle D Williams; Dianna B Roberts; Merrill S Kies; Li Mao; Randal S Weber; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

Review 6.  Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.

Authors:  Amalia Milano; Francesco Longo; Maria Basile; Rosario V Iaffaioli; Francesco Caponigro
Journal:  Oral Oncol       Date:  2007-03-09       Impact factor: 5.337

Review 7.  What is new in the management of salivary gland cancers?

Authors:  David J Adelstein; Cristina P Rodriguez
Journal:  Curr Opin Oncol       Date:  2011-05       Impact factor: 3.645

8.  Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma.

Authors:  A Felix; A K El-Naggar; M F Press; N G Ordonez; I Fonseca; S L Tucker; M A Luna; J G Batsakis
Journal:  Hum Pathol       Date:  1996-06       Impact factor: 3.466

9.  Prognostic values of pathologic findings and hypoxia markers in 21 patients with salivary duct carcinoma.

Authors:  Jong-Lyel Roh; Kyung-Ja Cho; Gui Young Kwon; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Surg Oncol       Date:  2008-06-01       Impact factor: 3.454

10.  Salivary duct carcinoma.

Authors:  A Sefik Hosal; Chunyang Fan; Leon Barnes; Eugene N Myers
Journal:  Otolaryngol Head Neck Surg       Date:  2003-12       Impact factor: 5.591

View more
  14 in total

1.  Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study.

Authors:  Jalal B Jalaly; Souzan Sanati; Rebecca D Chernock; Dikson G Dibe; Samir K El-Mofty
Journal:  Head Neck Pathol       Date:  2018-01-04

2.  Salivary duct carcinoma: A clinopathological report of 11 cases.

Authors:  Xiaofeng Huang; Jing Hao; Sheng Chen; Runzhi Deng
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

3.  Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report.

Authors:  Kenta Kawahara; Akimitsu Hiraki; Ryoji Yoshida; Hidetaka Arita; Yuichiro Matsuoka; Toshio Yamashita; Kan-Ichi Koga; Masashi Nagata; Akiyuki Hirosue; Daiki Fukuma; Hideki Nakayama
Journal:  Mol Clin Oncol       Date:  2017-04-21

4.  Clinical value of adjuvant therapy on the prognosis of ductal carcinoma of the major salivary gland: a large-scale cohort study.

Authors:  Di Zhang; Lixi Li; Tingyu Wen; Fei Ma
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-08-29       Impact factor: 3.236

Review 5.  Recent advances in the diagnostic pathology of salivary carcinomas.

Authors:  Roderick H W Simpson; Alena Skálová; Silvana Di Palma; Ilmo Leivo
Journal:  Virchows Arch       Date:  2014-08-30       Impact factor: 4.064

6.  Early T Stage Salivary Duct Carcinoma: Outcomes and Implications for Patient Counseling.

Authors:  Nicole C Schmitt; Arun Sharma; Mark R Gilbert; Seungwon Kim
Journal:  Otolaryngol Head Neck Surg       Date:  2015-08-25       Impact factor: 3.497

7.  A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.

Authors:  Mark R Gilbert; Arun Sharma; Nicole C Schmitt; Jonas T Johnson; Robert L Ferris; Umamaheswar Duvvuri; Seungwon Kim
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-05-01       Impact factor: 6.223

Review 8.  Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.

Authors:  Nicole C Schmitt; Hyunseok Kang; Arun Sharma
Journal:  Oral Oncol       Date:  2017-09-21       Impact factor: 5.337

9.  Postoperative radiotherapy in patients with salivary duct carcinoma: clinical outcomes and prognostic factors.

Authors:  Makoto Shinoto; Yoshiyuki Shioyama; Katsumasa Nakamura; Torahiko Nakashima; Naonobu Kunitake; Yuichiro Higaki; Tomonari Sasaki; Saiji Ohga; Tadamasa Yoshitake; Kayoko Ohnishi; Kaori Asai; Hideki Hirata; Hiroshi Honda
Journal:  J Radiat Res       Date:  2013-04-04       Impact factor: 2.724

10.  Salivary Duct Carcinoma of the Deep Lobe of the Parotid Gland: A Rare Clinical Finding.

Authors:  Hi-Jin You; Tae-Kyoung Yun; Seong-Ho Jeong; Eun-Sang Dhong; Seung-Kyu Han
Journal:  Arch Plast Surg       Date:  2016-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.